With Record Growth Of Its Simoa Accelerator Lab, Quanterix Invites Academics, Clinical Researchers And Scientists To Apply For A Grant To Further Biomarker Research

Leading provider of ultrasensitive single molecule measurement technology expands lab and opens a call for proposals to stimulate local innovation

LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a leader in ultrasensitive single molecule measurement for the benefit of human health, today announced continued momentum of its Simoa Accelerator Lab, a dedicated laboratory environment for custom assay development and clinical sample testing. Since its launch in 2014, the Lab has grown from one to four instruments, expanding its capabilities to run up to 2,000 different samples a day. Continuing this momentum and furthering the Company’s mission to stimulate rapid growth and innovation in healthcare, Quanterix invites organizations, academics and independent researchers to submit research proposals for a chance to secure a grant for access to the revolutionary Single Molecule Array (Simoa) HD-1 Analyzer, and this state-of-the-art Lab.

“We have an opportunity to change the paradigm of today's sickcare to true healthcare with our Simoa technology and, as such, we feel a responsibility to put it in the hands of as many people as possible”

With nearly 70 completed projects in 2014 from organizations across 17 states and 8 countries in EMEA, the Company has dramatically increased the size of its testing lab to accommodate demand. To celebrate this growth, Quanterix will award an organization and/or independent researcher access to its Simoa Accelerator Lab and corresponding assays for exploration of new biomarkers and pathways in a broad array of fields, including oncology, neurology, cardiology and other fields of medicine. To be considered for the research grant, applicants should visit http://info.quanterix.com/simoa-accelerator-lab-call-for-proposals and fill out a short application before the June 10, 2015 deadline.

“We have an opportunity to change the paradigm of today's sickcare to true healthcare with our Simoa technology and, as such, we feel a responsibility to put it in the hands of as many people as possible,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “This was the strategy behind the launch of the Accelerator Lab last year and we’re excited to see the continued global demand for its services. Today, we are celebrating the growth of the facility by opening its doors and fueling the discovery of new biomarkers to one deserving recipient. We will be evaluating each proposal closely for its ability to unlock a world of insight into disease detection, diagnosis and patient treatment.”

Simoa Accelerator Lab customers include the majority of the top global pharmaceutical and biotechnology companies, CROs and leading academic and government institutions. The winning applicant will be awarded complete access to the Lab and the opportunity to work side-by-side with Quanterix scientists while samples are run to gain hands-on experience with the Simoa HD-1 Analyzer. The applicant can expect to receive reliable, high quality data to further their research with 1,000 time greater sensitivity than ever before.

For more information on the Simoa Accelerator Lab and to apply for this opportunity, please visit: http://info.quanterix.com/simoa-accelerator-lab-call-for-proposals.

About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.